If you're part of a CRO or a sponsor, you know that you don't usually lose a clinical trial timeline because paid ads didn't run, but usually because the advertising funnel doesn't attract the right participants, meaning the study still misses its enrollment date.
This happens because recruitment and enrollment are two different jobs, measured by two different numbers. Recruitment generates interest, while enrollment turns that interest into a qualified, consenting, randomized study participant. Most of what happens in between never shows up in a cost-per-lead report.
This guide defines patient enrollment in clinical trials, walks the funnel stage by stage, and shows where ad and referral quality actually move the number that decides whether a trial enrolls on schedule.
What is patient enrollment in clinical trials?
Patient enrollment in clinical trials is the stage that begins once a referral exists and ends when a qualified, consenting person is formally entered into a study protocol. It sits downstream of recruitment, the advertising, outreach, and awareness work that generates interest in the first place.
Four steps make up enrollment. Pre-screening asks basic history and demographic questions, usually by phone or an online form, to catch obvious mismatches early. Eligibility screening checks a referral against the study's inclusion and exclusion criteria, often through lab work or a clinical exam. Informed consent discloses the study's risks, benefits, and the participant's rights, and requires a signature before anything else proceeds. Randomization formally enters a consented, eligible patient into the trial protocol, sometimes into a specific study arm.
Each step can end a person's path through the funnel. A referral that clears pre-screening can still fail eligibility screening. Someone who is eligible can decline to consent. Enrollment counts only the people who make it through all four steps, which is why enrollment and recruitment numbers rarely move together.
Recruitment vs. enrollment: where one ends and the other begins
Recruitment is everything that generates a referral. Enrollment is everything that happens to that referral once it exists.
Recruitment covers advertising, outreach, patient-facing content, and any awareness work designed to get someone to raise a hand. Its job ends the moment a person fills out a form, calls a number, or clicks through to a screening page. Everything after that belongs to enrollment: pre-screening, eligibility checks, consent, and randomization.
The distinction matters because the two stages fail for different reasons and respond to different fixes. A recruitment problem shows up as too few referrals, or referrals that cost too much to generate. An enrollment problem shows up as referrals that arrive but never convert to randomized patients. No amount of extra ad spend fixes that on its own.
Sponsors who track only cost per lead are measuring recruitment and assuming enrollment will follow. It often doesn't.
The patient enrollment funnel, stage by stage
The patient enrollment funnel runs from referral to pre-screen to eligibility screening to informed consent to randomization, and each stage loses a share of the people who entered it.
A referral enters the funnel when someone responds to an ad, outreach effort, or provider mention and expresses interest. Pre-screening follows within days, usually a short phone call or online form that checks basic history, location, and obvious disqualifiers. Eligibility screening goes deeper: lab tests, imaging, or a clinical exam measured against the protocol's inclusion and exclusion criteria. This is typically where the largest drop-off happens, because criteria are often stricter than a referral realized going in.
Informed consent comes next. Site staff walk the eligible patient through the study's risks, benefits, time commitment, and right to withdraw. The patient signs before anything further happens. Randomization is the final step: the patient is formally entered into the protocol, sometimes assigned to a specific treatment arm.
Each stage has its own owner and its own drop-off rate, which is why treating "enrollment" as one number hides where the funnel actually breaks.
Why patients drop off between referral and randomization
Most enrollment loss traces back to three causes: eligibility criteria that turn out stricter than the ad promised, low trust or awareness of the specific trial, and the burden participation places on a patient's time and travel.
Criteria mismatches happen when an ad targets broadly rather than around the protocol's actual inclusion and exclusion rules. A referral who was never going to qualify still costs money to generate, and still occupies a call-center or site coordinator's time before failing screening. Trust and awareness gaps show up when a referral doesn't recognize the trial's sponsor, doesn't understand what participation involves, or has never heard of the specific condition-focused study before clicking. Burden shows up later: once someone is asked to commit to travel, repeat visits, or a multi-month protocol, some referrals who were otherwise eligible decline.
The first cause is the one media buying controls directly. A referral that never matched the eligibility profile in the first place was never enrollable, no matter how well the site runs pre-screening or consent.
Screen-fail economics: what a disqualified referral actually costs
Every referral that fails pre-screen or eligibility screening still costs money to generate, so the real efficiency metric is cost per randomized patient, not cost per lead.
A campaign with a cheap cost per lead can still be expensive per enrolled patient if most of its referrals fail screening. A campaign with a more expensive cost per lead can be cheaper per enrolled patient if its referrals survive screening at a much higher rate. Cost per lead alone can't tell the two apart, which is why it's a misleading headline metric on its own.
There is no universal benchmark for screen-fail rate or cost per randomized patient. Both vary by therapeutic area, phase, and how tightly a protocol writes its inclusion and exclusion criteria. The ratio between the two figures is worth tracking: how much of what gets spent generating a lead actually survives screening to become a randomized, enrolled patient.
Why referral quality, not just referral volume, decides enrollment rate
The single biggest lever on enrollment rate is whether an ad's targeting and messaging pre-qualify the viewer before they ever click. A referral that already resembles the eligibility profile survives pre-screening and eligibility screening at a much higher rate than one generated by broad, low-relevance targeting. Getting that pre-qualification right is a media-buying discipline, not a site-operations fix.
Brighter Click's clinical-trials practice is geo-targeted paid media built around IRB ad-approval and FTC advertising rules, for CROs and healthtech brands recruiting patients into active studies, not UGC production.
On the Adams Clinical account, that focus on referral quality produced a 45.9 percent decrease in cost per lead alongside a 91.5 percent increase in click-to-conversion rate. That result is evidence that funnel-quality work, not just added spend, moves an enrollment number.
Sponsors and CROs evaluating a recruitment partner can see what a CRO recruitment engagement includes before deciding whether a funnel-quality audit fits an active study.
How to improve patient enrollment rates
Three levers actually move enrollment rate: pre-qualifying audiences before the click, front-loading the highest-signal disqualifying questions in the pre-screener, and keeping IRB-approved creative ready in batches so testing doesn't stall on approval cycles.
The first lever is geo-targeted, condition-aware ad audiences built to mirror the protocol's eligibility profile, so a referral is more likely to survive screening before it ever reaches a call center. The second is pre-screener design: asking the highest-signal disqualifying questions first, so a referral who was never going to qualify exits the funnel before it costs a call-center touch or a site coordinator's time. The third is keeping IRB-approved creative variants ready in batches, so message testing doesn't stall waiting on a single approval cycle.
Compliance sits underneath all three. The real exposure for recruitment advertising is FTC rules and state advertising law, plus IRB review of any patient-facing material before it runs. Once a lead moves into a CRM or call-center intake step, the health information it generates falls under separate data-handling rules, a distinct question from the advertising itself.
Whether sponsors run this in-house or bring in a partner, they can start by comparing clinical trial recruitment partners against pre-qualification, pre-screener design, and creative-approval speed.
Measuring enrollment performance: the metrics that matter
Track enrollment rate as randomized patients divided by total qualified referrals, not leads divided by ad spend, because cost per lead alone hides a poor screen-fail rate.
Cost per lead alone can make a weak campaign look efficient right up until the enrollment count comes in short. Ask any recruitment partner to report cost per randomized patient alongside cost per lead, and to break out screen-fail rate by stage rather than as one blended number.
Sponsors can see how healthcare brands report on paid media for a broader look at the reporting standards CROs and healthtech marketers should expect from a paid-media partner.
Enrollment efficiency starts with an agency who knows referral quality
Enrollment efficiency is a media-quality question as much as a clinical-operations one. The funnel between referral and randomization is where trial timelines actually slip. Referral quality is the lever a paid-media partner controls directly.
Book a strategy call with Brighter Click to walk through what a funnel-quality audit would look like for an active study.
FAQ
What is the difference between patient recruitment and patient enrollment in clinical trials?
Recruitment is everything that generates a referral: advertising, outreach, and awareness. Enrollment is everything that happens after a referral exists: pre-screening, eligibility screening, informed consent, and randomization into the study protocol. A person is recruited once they express interest, and enrolled once they qualify, consent, and are formally entered into the trial. The two stages fail differently, so sponsors should measure them separately rather than as one funnel.
Is it true that 80 percent of clinical trials fail to meet enrollment timelines?
Most clinical trials do miss their original enrollment timelines, though the exact share depends on source, phase, and therapeutic area, and published figures range widely from study to study. The operational point holds regardless: enrollment, not recruitment volume, is where most trial timelines slip.
What are the barriers to patient enrollment in clinical trials?
The main barriers are strict eligibility criteria, low patient awareness or trust in a specific trial, and the burden of participation, including travel and time commitments. One barrier gets less attention: referral quality. When ad targeting attracts people who never matched the inclusion criteria, those referrals fail screening no matter how well a site runs its process. Reducing barriers starts upstream, with media that pre-qualifies patients before they click.
How is patient enrollment rate calculated?
Enrollment rate is the number of randomized patients divided by the total number of qualified referrals over the same period. Many teams also track patients enrolled per site per month against the study's target. Cost per lead alone hides a poor screen-fail rate, so sponsors should ask any recruitment partner to report cost per randomized patient alongside it.
What causes a high screen-fail rate in clinical trials?
A high screen-fail rate usually means the referrals entering the funnel never matched the protocol's inclusion and exclusion criteria. Common causes include broad ad targeting, messaging that overpromises eligibility, pre-screener questions asked too late to filter people out early, and criteria stricter than the campaign communicated. Every failed referral still costs money to generate, so screen-fail rate is as much a media-quality problem as a clinical-operations one.
How many patients are usually in a clinical trial?
It depends on the phase. The FDA's description of the clinical research process puts Phase 1 trials at roughly 20 to 80 participants, Phase 2 trials at up to several hundred, and Phase 3 trials at roughly 300 to 3,000. Those targets set the enrollment math for recruitment planning: the larger the phase, the more qualified referrals the funnel must produce to randomize enough patients on schedule.
